MX2020011558A - Imidazolonyl quinolines and use thereof as atm kinase inhibitors. - Google Patents
Imidazolonyl quinolines and use thereof as atm kinase inhibitors.Info
- Publication number
- MX2020011558A MX2020011558A MX2020011558A MX2020011558A MX2020011558A MX 2020011558 A MX2020011558 A MX 2020011558A MX 2020011558 A MX2020011558 A MX 2020011558A MX 2020011558 A MX2020011558 A MX 2020011558A MX 2020011558 A MX2020011558 A MX 2020011558A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- imidazolonyl
- quinolines
- atm kinase
- het
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- XRKYMMUGXMWDAO-UHFFFAOYSA-N 2-(4-morpholinyl)-6-(1-thianthrenyl)-4-pyranone Chemical compound O1C(C=2C=3SC4=CC=CC=C4SC=3C=CC=2)=CC(=O)C=C1N1CCOCC1 XRKYMMUGXMWDAO-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to compounds of the formula (I), wherein R1, R3, Het<sup>1</sup> and HET have the meanings specified in claim 1, are ATM kinase inhibitors and can be used, inter alia, for treating cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15000968 | 2015-04-02 | ||
PCT/EP2016/000542 WO2016155884A1 (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011558A true MX2020011558A (en) | 2022-03-09 |
Family
ID=52814780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011558A MX2020011558A (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors. |
MX2017012613A MX2017012613A (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017012613A MX2017012613A (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors. |
Country Status (24)
Country | Link |
---|---|
US (5) | US10457677B2 (en) |
EP (3) | EP3560924B1 (en) |
JP (2) | JP6791873B2 (en) |
KR (2) | KR102652052B1 (en) |
CN (3) | CN107889488B (en) |
AU (3) | AU2016239270B2 (en) |
BR (1) | BR122019005502B1 (en) |
CA (1) | CA2981365A1 (en) |
DK (2) | DK3560924T3 (en) |
ES (3) | ES2946507T3 (en) |
HR (2) | HRP20191396T1 (en) |
HU (2) | HUE045477T2 (en) |
IL (3) | IL254714B (en) |
LT (2) | LT3560924T (en) |
MX (2) | MX2020011558A (en) |
PL (2) | PL3277681T3 (en) |
PT (2) | PT3277681T (en) |
RS (2) | RS59139B1 (en) |
RU (1) | RU2743343C2 (en) |
SG (2) | SG11201708065QA (en) |
SI (2) | SI3277681T1 (en) |
TR (1) | TR201911244T4 (en) |
WO (1) | WO2016155884A1 (en) |
ZA (1) | ZA201707423B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743343C2 (en) * | 2015-04-02 | 2021-02-17 | Мерк Патент Гмбх | Imidazolonyl quinolines and use thereof as kinase atm inhibitors |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
CN110312717B (en) * | 2017-02-27 | 2022-04-12 | 上海瑛派药业有限公司 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and uses thereof |
JOP20190209A1 (en) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
EP3737383A4 (en) | 2018-01-12 | 2021-12-15 | Prolynx LLC | Synergistic cancer treatment |
RU2020133020A (en) * | 2018-03-14 | 2022-04-14 | Мерк Патент Гмбх | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUMOR IN A SUBJECT |
IL277777B2 (en) | 2018-04-12 | 2023-10-01 | Bayer Ag | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides |
WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
CN110386932A (en) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | For the dual ATM and DNA-PK inhibitor in antitumor therapy |
GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
CN109045042A (en) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Application of the ATM inhibitor in the drug that preparation inhibits acute lymphatic leukemia recurrence |
KR102345208B1 (en) * | 2018-09-30 | 2021-12-30 | 메드샤인 디스커버리 아이엔씨. | Quinolino-pyrrolidin-2-one derivatives and their applications |
WO2020193660A1 (en) | 2019-03-27 | 2020-10-01 | Merck Patent Gmbh | Imidazolonylquinoline compounds and therapeutic uses thereof |
BR112022001067A2 (en) * | 2019-07-30 | 2022-05-24 | Xrad Therapeutics Inc | Dual atm and dna-pk inhibitors for use in antitumor therapy |
CN114615995A (en) | 2019-11-01 | 2022-06-10 | 阿雷斯贸易股份有限公司 | Combined inhibition of PD-1, TGF beta and ATM and radiotherapy for cancer treatment |
AU2020398215A1 (en) * | 2019-12-04 | 2022-06-16 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
WO2021139814A1 (en) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | Quinoline imidazole compound and application thereof |
CN115380031A (en) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | Crystal form of quinoline pyrrolidine-2-ketone compound as ATM inhibitor and application thereof |
CN115916203A (en) * | 2020-06-18 | 2023-04-04 | 默克专利股份公司 | Compounds for the treatment of viral infections |
EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
CA3190226A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Pharmaceutical preparation |
AU2020468487B2 (en) | 2020-09-21 | 2024-02-29 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
CN115232122B (en) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术(石家庄)有限公司 | Alkyne compound as well as preparation and application thereof |
CN115716829B (en) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | Quinoline imidazole ketone-deuterium-substituted pyrazole compound and application thereof |
WO2024112796A1 (en) * | 2022-11-23 | 2024-05-30 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
DK1879893T3 (en) * | 2005-03-21 | 2010-09-13 | Ferrer Int | Process for the Preparation of 1-Substituted 1H-Imidazo [4,5-c] Quinoline-4-Amine Compounds and Intermediates |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN104758288A (en) | 2007-02-20 | 2015-07-08 | 诺华股份有限公司 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors |
CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
RU2545023C9 (en) * | 2008-06-10 | 2016-06-20 | Эббви Инк. | Tricyclic compounds, pharmaceutical composition containing them and using them for treating immunological and oncological compounds |
RU2519200C2 (en) | 2008-10-01 | 2014-06-10 | Новартис Аг | Using smoothened antagonists for treating hedgehog pathway related disorders |
EP2438063A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases |
WO2010139731A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CN102803227B (en) * | 2010-03-16 | 2016-01-20 | 默克专利有限公司 | morpholinyl quinazoline |
EA201300052A1 (en) * | 2010-06-28 | 2013-06-28 | Мерк Патент Гмбх | [1,8] NAPHTHYRID DERIVATIVES |
CN102372711B (en) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | Imidazo quinoline PI3K and mTOR (mammalian target of rapamycin) dual inhibitor |
DE102010035744A1 (en) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
CN102399218A (en) | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | Triheterocyclic compounds and their use as PI3K inhibitors |
US20130245061A1 (en) | 2010-12-03 | 2013-09-19 | Novartis Ag | Pharmaceutical compositions |
CN103012398B (en) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | Imidazoquinoline analog derivative and pharmacologically acceptable salt thereof, its preparation method and in application pharmaceutically |
WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
BR112014030099A2 (en) | 2012-06-06 | 2017-06-27 | Novartis Ag | combination of a 17-alpha hydroxylase inhibitor (c17,20-lyase) and a specific pi-3 k inhibitor for treating a tumor disease |
NO2714752T3 (en) * | 2014-05-08 | 2018-04-21 | ||
RU2743343C2 (en) | 2015-04-02 | 2021-02-17 | Мерк Патент Гмбх | Imidazolonyl quinolines and use thereof as kinase atm inhibitors |
-
2016
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/en active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/en unknown
- 2016-03-31 ES ES21165573T patent/ES2946507T3/en active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/en unknown
- 2016-03-31 SI SI201630345T patent/SI3277681T1/en unknown
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/en active Active
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/en active IP Right Grant
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/en active
- 2016-03-31 PL PL19172903T patent/PL3560924T3/en unknown
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/en unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/en unknown
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/en unknown
- 2016-03-31 MX MX2020011558A patent/MX2020011558A/en unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/en active Active
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/en active Active
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/en active
- 2016-03-31 PT PT191729037T patent/PT3560924T/en unknown
- 2016-03-31 ES ES19172903T patent/ES2880626T3/en active Active
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/en active Active
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/en unknown
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/en active Active
- 2016-03-31 SI SI201631240T patent/SI3560924T1/en unknown
- 2016-03-31 RS RS20210817A patent/RS62082B1/en unknown
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/en active Application Filing
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/en active Pending
- 2016-03-31 MX MX2017012613A patent/MX2017012613A/en active IP Right Grant
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/en unknown
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/en active IP Right Grant
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/en active Pending
- 2016-03-31 ES ES16717560T patent/ES2741853T3/en active Active
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/en active Search and Examination
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/en unknown
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-08-01 HR HRP20191396 patent/HRP20191396T1/en unknown
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/en active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/en unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en active Pending
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011558A (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors. | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
MX2022002581A (en) | Benzimidazole compounds as c-kit inhibitors. | |
CR20200518A (en) | Pyridazinones as parp7 inhibitors | |
PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
MD20170070A2 (en) | Quinazoline derivatives used to treat HIV | |
MX2015013481A (en) | Fused heterocyclic compounds as protein kinase inhibitors. | |
MX371312B (en) | Pyrazolyl-ureas as kinase inhibitors. | |
MD20170016A2 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
MX2018008362A (en) | Quinolin-2-one derivatives. | |
MY173126A (en) | Arylquinazolines | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
MX2014002683A (en) | Benzonitrile derivatives as kinase inhibitors. | |
PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
MX2016015565A (en) | Certain protein kinase inhibitors. | |
MX2017003930A (en) | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds. | |
MX2018015247A (en) | Biarylmethyl heterocycles. | |
NZ730981A (en) | Boronic acid derivatives | |
MX2017004043A (en) | Boronic acid derivatives. | |
MX2017004037A (en) | Boronic acid derivatives. | |
MX370336B (en) | Boronic acid derivatives. | |
PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
MA39824A (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 |